Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial
- PMID: 37914474
- DOI: 10.1016/S2352-3026(23)00308-3
Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial
Conflict of interest statement
PM declares grants for research, advisory board membership, and speaker's bureaus from Daiichi Sankyo, Abbvie, Jazzpharma, Pfizer, and Bristol-Myers Squibb. CS-M declares grants from research from Amgen, speaker's bureaus from Astellas, Abbvie, Abbot, and Pfizer.
Comment on
-
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.Lancet Haematol. 2023 Nov;10(11):e879-e889. doi: 10.1016/S2352-3026(23)00273-9. Lancet Haematol. 2023. PMID: 37914482 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
